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Introduction
Cardiovascular disease (CVD) is a major health problem and is one of the leading causes of death in industrialized countries. 1, 2 It is a multifactorial complex disease, composed of several vascular disorders and many factors contribute to the risk of CVD. One of the major risk factors for CVD is high serum cholesterol, especially increased serum low-density lipoprotein (LDL). 3 Pharmacological interventions, principally lipid-lowering therapy, are an essential component of the clinical management of CVD. [3] [4] [5] The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, have shown to be beneficial for primary and secondary prevention of CVD, due to their cholesterol-lowering activity. [6] [7] [8] [9] [10] [11] Statins competitively inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the cholesterol biosynthesis pathway. This leads to the upregulation of LDL-receptor activity and reduced secretion of apolipoprotein B (apoB)-containing lipoproteins from the liver, both of which contribute to lowering of the LDL-cholesterol concentration in plasma. 12, 13 By this mechanism, statins have the potential to protect against cardiovascular morbidity and mortality.
Nevertheless, there is a considerable variability between individuals in response to statins, in terms of both cholesterollowering and clinical outcomes, of which the origins are poorly understood. A part of this variation may be explained by genetic factors. 14, 15 Pharmacogenetics focuses on genetic polymorphisms that influence response to drug therapy. Over the past decade, many studies have focused on identifying potential genetic determinants regarding response to statin therapy. Markers that are predictive of statin efficacy or the occurrence of statin-related adverse drug reactions could be useful in tailoring treatment, based on individual subjects or certain subgroups.
Because statins have an influence on serum cholesterol concentration, single nucleotide polymorphisms (SNPs) in genes involved in the lipid metabolism may be involved in the interindividual variability in cholesterol response to statin therapy. In this study, we investigated whether common variation in genes involved in lipid metabolism modify the effect of statins on total serum cholesterol concentration.
Materials and methods
Setting
The Rotterdam Study is a prospective population-based cohort study of chronic diseases in the elderly population. From 1990 to 1993, all inhabitants of Ommoord, a district of the city of Rotterdam in the Netherlands, aged 55 years or over, were invited to participate (n ¼ 10 278) in the Rotterdam Study I (RS-I). Of them, 78% (n ¼ 7983) gave the written informed consent, including permission for retrieval of medical records, use of blood and DNA for research purposes, and publication of obtained results. The medical ethics committee of the Erasmus Medical Center, Rotterdam, the Netherlands, approved the study. Baseline examinations took place from March 1990 through July 1993. Follow-up examinations were conducted periodically, every 4-5 years. The cohort was continuously being monitored for major morbidity and mortality through linkage of the Rotterdam Study database with general practitioner and municipality records. Furthermore, exposure to medication was continuously monitored since 1 January 1991, through fully computerized pharmacy records from the seven linked pharmacies in the Ommoord district. Information on all dispensed drugs was available in computerized format on a day-to-day basis. The data consisted of information on the date of prescribing, the total amount of drug units per prescription, the prescribed daily number of units, the product name of the drugs and the Anatomical Therapeutic Chemical code. DNA for genotyping was available for 6571 (82%) participants from the baseline visit.
Furthermore, in 2000, an extended cohort was enrolled, the Rotterdam Study II (RS-II). All inhabitants of Ommoord, aged 55 years or older and not enrolled in the RS-I, were invited to participate in this extended cohort (n ¼ 5404). Of them, 3011 (67%) entered the study and took part in the baseline examination . The second visit for the RS-II took  place between 2004 and 2005. Detailed information on design, objectives and methods of the Rotterdam Study has been given elsewhere. 16, 17 Study population The source population consisted of all participants of the RS-I, who were successfully genotyped as part of a large population-based project on genetics of complex traits and diseases, financed by the Dutch government through the Netherlands Scientific Organization-Large Investments (NWO Groot 175.010.2005.011) (n ¼ 5974). The study population consisted of all participants of the RS-I, who received a prescription for statin therapy in the study period between 1 April 1991 and 1 January 2008, and who had at least one serum cholesterol measurement available at any time during the study period after prescription of statin therapy (n ¼ 554).
Outcome definition
In this study, the outcome of interest was cholesterol response to statin therapy. For every statin user in the population, the first serum total cholesterol measurement after start of prescription of statin therapy was defined as the outcome variable, with the date of cholesterol measurement at least 1 week after the prescription date of statin therapy. This first cholesterol measurement was considered as a measure of cholesterol response to statin therapy. In the Rotterdam Study, serum cholesterol levels are assessed at baseline examination and subsequently during follow-up examinations. As of April 1997, also fasting total cholesterol levels assessed between follow-up examinations as part of patient care were gathered by linkage to the general practitioners' laboratory 'Stichting Artsenlaboratorium Rotterdam en Omstreken' (Starlab).
Genotyping and SNP selection
At the baseline examination of the Rotterdam Study, blood was taken from which genomic DNA was extracted, using the salting-out method. 18 Microarray genotyping was performed in the whole original Rotterdam Study cohort using the Infinium II HumanHap550K Genotyping BeadChip version 3 (Illumina Inc., San Diego, CA, USA). Genotyping procedures were followed according to the manufacturer's protocols. Microarray genotyping procedures in the Rotterdam Study have been previously described. 19 In this study the selection of SNPs was performed, using a candidate gene approach. On the basis of literature, 13, 20, 21 we selected 18 genes involved in lipid metabolism. The selected genes were HMGCR, squalene synthase (FDFT1), cholesterol 7a hydroxylase (CYP7A1), LDL-receptor (LDLR), APOB, apolipoprotein E (APOE), apolipoprotein A-I (APOA1), cholesteryl ester transfer protein (CETP), ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G8 (ABCG8), paraoxonase 1 (PON1), sterol regulatory element-binding protein 1 (SREBF1), peroxisome proliferator-activated receptor-d (PPARD), peroxisome proliferator-activated receptor-g (PPARG), lipoprotein lipase (LPL), hepatic lipase (LIPC), microsomal triglyceride transfer protein (MTP) and leptin receptor (LEPR). Markers were excluded if they deviated significantly from HardyWeinberg equilibrium (Po1 Â 10 À4 ), if they had a low minor allele frequency (MAFo0.05) or if they had an SNP call rate o95% within the samples. All SNPs present within the gene area of each individual gene ± 50 kb were extracted from the data set. This resulted in a data set of 667 SNPs in total for the 18 candidate genes together.
Covariates
The following covariates were considered as potential determinants for affecting the association between genotype and serum total cholesterol concentration in a population only consisting of statin users: age, gender, baseline total cholesterol, high-density lipoprotein (HDL)-cholesterol at baseline, average defined daily dose of statin therapy and duration of statin use. During the baseline visit at the research center, nonfasting blood samples were obtained, and serum lipid parameters of total cholesterol and HDLcholesterol were determined by an enzymatic procedure. 22 The prescribed dose of statin therapy is given as the average defined daily dose, calculated as the total defined daily dose of statin therapy over the total follow-up time divided by the total number of days of exposure over the same time period. Duration of statin use is defined as the time between the prescription date of statin therapy and the date of first serum total cholesterol measurement after at least 1 week of statin therapy.
Analysis
Differences in baseline characteristics between statin users and the source population were tested using a w 2 -test for binary variables and a t-test for continuous variables. HardyWeinberg equilibrium was tested using a w 2 -test. We performed two statistical analyses in a stepwise approach. First, we investigated which of all selected SNPs (n ¼ 667) influenced the cholesterol response to statin therapy, by using linear regression analysis with Plink version 1.01 (Purcell et al., Boston, MA, USA). 23 All selected SNPs were tested on total cholesterol concentration after start of statin therapy under an additive model, adjusted for age, gender, baseline cholesterol, HDL-cholesterol at baseline, statin dose and duration of statin use. To take into account the problem of multiple testing, per individual gene, we applied a Bonferroni correction for the number of SNPs within the gene region. The Bonferroni P-value was calculated by multiplying the observed P-value by the number of SNPs tested for association within the gene region. Because a priori candidate genes in the lipid metabolism were selected based on literature, Bonferroni correction was performed per individual gene. Selected on this Bonferroni P-value, the promising SNPs were also studied in a replication cohort, to reduce the chance of reporting a false-positive association. Because our aim was to investigate polymorphisms that influence cholesterol concentration in response to statin therapy, and not polymorphisms that influence cholesterol concentration in general, we also performed a linear regression analysis on baseline cholesterol in non-statin users to investigate the relationship between each SNP and baseline cholesterol. This linear regression was performed on all subjects who had not received any statin at baseline and who had a baseline cholesterol measurement available (n ¼ 5749).
The SNPs that showed a Po0.1 after Bonferroni correction, and were not significantly related to baseline cholesterol, were further analyzed. We tested the remaining SNPs in a genotypic model on cholesterol concentration after start of statin therapy, using SPSS for Windows software, version 15.0 (SPSS Inc., Chicago, IL, USA). We compared cholesterol concentration after start of statin therapy between the different genotype categories, whereby we adjusted for age, gender, baseline cholesterol, HDL-cholesterol at baseline, statin dose and duration of statin use.
Replication
To avoid the reporting of a false-positive association, we repeated the analysis for those SNPs that showed a significant effect on cholesterol concentration in response to statin therapy in the discovery cohort (RS-I). This replication study was performed in an independently collected cohort, the RS-II. The source population for replication consisted of all participants in the RS-II, who were successfully genotyped (n ¼ 1895). The study population consisted of those subjects in the source population who received a prescription for statin therapy in the study period between baseline date and 1 January 2008, and who had at least one serum cholesterol measurement available at any time during the study period at least 1 week after prescription of statin therapy (n ¼ 243). The outcome variable was cholesterol concentration after start of statin therapy, as described earlier. We performed a linear regression analysis, in which both SNPs were tested in an additive and a genotypic model. We compared cholesterol concentration after start of statin therapy between the different genotype categories, whereby we adjusted for age, gender, baseline cholesterol, HDL-cholesterol at baseline, statin dose and duration of statin use. Finally, we performed a fixed effect inverse variance meta-analysis to combine the results of the original analysis (RS-I) and the results of the replication analysis (RS-II).
Results
Population characteristics
The baseline characteristics of the source and study population (RS-I) are shown in Table 1 . Overall, the source population consisted of all subjects, of whom genotype data were available (n ¼ 5974). The mean age in the population was approximately 69.4 years and 59.4% of the total population were women. For the analysis on cholesterol response to statin therapy the study population consisted of all subjects who received statin therapy between 1 April 1991 and 1 January 2008 (n ¼ 554). For all these 554 statin users, a serum cholesterol measurement at least 1 week after start of statin therapy was available. The median time between the prescription date of statin therapy and the date of first serum total cholesterol measurement was 80 days (interquartile range: 40-174 days), with a minimum of 8 days and a maximum of 1068 days. The average defined daily dose of statin therapy was 1.12 (s.d.: ±0.71). Of the different kind of statins, simvastatin was prescribed most frequently (n ¼ 337, 60.8%), followed by atorvastatin (n ¼ 108, 19.5%) and pravastatin (n ¼ 66, 11.9%).
Cholesterol response
Of all 667 SNPs, only 2 showed evidence for association with cholesterol response to statin therapy under an additive model, after Bonferroni correction at a liberal P-value of o0.1. The two SNPs that remained under this P-value threshold were the SNP rs1532624 in the CETP gene (b: 0.153, original P-value 0.002, Bonferroni P-value 0.084) and the SNP rs533556 in the APOA1 gene (b: 0.140, original P-value 0.004, Bonferroni P-value 0.039). Both SNPs were not related to baseline total cholesterol in non-statin users in the discovery cohort (RS-I).
The results of the linear regression analysis on cholesterol concentration after start of statin therapy under a genotypic model are shown in Table 2 . Subjects with a minor allele of the SNP rs1532624 in the CETP gene showed a higher cholesterol concentration after start of statin therapy than subjects homozygous for the major allele, the reference category. This effect of genotype on cholesterol concentration was borderline nonsignificant for the heterozygous genotype compared with the homozygous major allele genotype (b: 0.144 mmol l À1 , P ¼ 0.054), and significant for the variant genotype compared with the homozygous major allele genotype (b: 0.281 mmol l À1 , P ¼ 0.006). In our population, the MAF of the rs1532624 SNP was 40.6% (A allele). Subjects with a minor allele of SNP rs533556 in the APOA1 gene showed a higher cholesterol concentration after start of statin therapy than subjects homozygous for the major allele, the reference category. This effect of genotype on cholesterol concentration was significantly different for both the heterozygous genotype and the homozygous variant allele genotype, compared with the homozygous major allele genotype (b: 0.178 mmol l À1 , P ¼ 0.014 and b: 0.246 mmol l À1 , P ¼ 0.021, respectively). In our study population, the MAF of the rs533556 SNP was 35.5% (A allele). Genotype distributions for the CETP genotype and the APOA1 genotype are given in Table 3 .
Replication
The baseline characteristics of the replication sample (RS-II) are shown in Table 1 . The statins used were comparable between the discovery cohort and the study population for replication. Also, the distribution of statin use was comparable between both cohorts, with in the replication cohort a median time of 78.5 days (interquartile range: 40-148 days) Table 3 . In the replication population, the MAF of the CETP rs1532624 SNP was 40.2% (A allele) and the MAF of the APOA1 rs533556 SNP was 37.7% (A allele). Both genotype distributions were in Hardy-Weinberg equilibrium.
Results of the linear regression analysis on cholesterol concentration after start of statin therapy under a genotypic model are shown in Table 4 . Subjects with a minor allele of the rs1532624 SNP in the CETP gene showed a higher cholesterol concentration after start of statin therapy than subjects homozygous for the major allele, the reference category. This effect of genotype on cholesterol concentration was significant for the variant genotype compared with the homozygous major allele genotype (effect: 0.460 mmol l À1 , P ¼ 0.006), but not significant for the heterozygous genotype compared with the homozygous major allele genotype (effect: 0.108 mmol l À1 , P ¼ 0.358). For the rs533556 SNP in the APOA1 gene, no significant difference in cholesterol concentration after start of statin therapy between the different genotype categories was observed.
The results of the fixed effect inverse variance metaanalysis are shown in Figure 1 
Discussion
In this study, we investigated whether SNPs in genes involved in the lipid metabolism modify the relationship between statin therapy and cholesterol response. We Genotype distributions for the CETP and APOA1 SNPs in the source population and study population, both for the discovery cohort and for the replication cohort. For both SNPs, genotype CC is homozygous for the major allele, genotype CA is heterozygous and genotype AA is homozygous for the variant allele.
showed a statistically significant association between the rs1532624 polymorphism, located in intron 7 of the CETP gene, and cholesterol response to statin therapy. Subjects with a variant allele of the polymorphism showed a significantly smaller cholesterol reduction after start of statin therapy. This association was replicated in an independent cohort, reducing the chance of a false-positive association. There appears to be a dose-allele effect: the cholesterol concentration was on average 0.16 mmol l
À1
higher per additional allele. We also demonstrated that subjects with at least one variant allele of the rs533556 in the APOA1 polymorphism showed a significantly smaller cholesterol reduction after start of statin therapy in the discovery sample, however this association failed to replicate. To the best of our knowledge, the SNP (rs1532624) identified in this study has not been described before in the literature in association with cholesterol response to statin therapy. Previous pharmacogenetic studies investigated the relationship between CETP gene polymorphisms and lipid concentration. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] The polymorphism in the CETP gene that is most frequently described is the noncoding mutation TaqIB SNP in intron 1. Several studies investigated the relationship between the TaqIB polymorphism and response to statin therapy. 25, 30, 31, [33] [34] [35] However, these studies used different study populations and examined different outcomes, for example, serum cholesterol concentrations, atherosclerosis progression and CVD outcomes, and the results are not conclusive. None of these studies showed a difference between the TaqIB genotype categories in total cholesterol concentration after start of statin therapy, the outcome variable we used in our study. Fiegenbaum et al. 33 showed a greater HDL cholesterol increase for the CETP B2B2 homozygotes than for B1B2 and B1B1 subjects (14.1 vs 1.7% and 1.3%, Po0.05) in response to simvastatin treatment, but no effect on total cholesterol was seen. De Grooth et al. 34 investigated the TaqIB polymorphism and change in total cholesterol, LDL-cholesterol and HDL-cholesterol, and reduction in nonfatal myocardial infarction and coronary heart disease 
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Beta ( mortality, in response to pravastatin treatment, but no difference between the genotype categories was shown. We have investigated whether the CETP rs1532624 SNP we found in this study was in linkage disequilibrium with the CETP TaqIB polymorphism. In our study, the TaqIB polymorphism was not available at the Illumina chip, but it was genotyped separately. The r 2 between the CETP TaqIB SNP and the CETP rs1532624 SNP was 0.88.
The main difference between our study and the previous pharmacogenetic studies is the way the SNPs were selected for analysis. Most studies comprised only a few SNPs, selected from known candidate genes in the cholesterol or statin metabolism, and known to be related to cholesterol. Although our study also used a candidate gene approach, we selected 18 genes all involved in the lipid metabolism from the literature. We aimed to identify those SNPs that define cholesterol concentration in response to statin therapy, and not SNPs that may define cholesterol concentration in general.
In this study, the assumption was made that a response to statin therapy was observed after at least 1 week of statin therapy. It might be argued that this period is too short for statins to exert an effect. In clinical trials, often at least a 4-week period of statin therapy is taken, before the outcome is measured. In our study, 15.5% of all statin users had a first serum total cholesterol measurement between 1 and 4 weeks after the prescription date of statin therapy. However, it is unlikely that this results in a bias, as the time between the prescription date of statin therapy and the date of first serum total cholesterol measurement is likely to be independent of genotype. Inclusion of the time between the prescription of statin therapy and the first serum total cholesterol measurement in the linear regression analysis did not affect the results. Furthermore, when comparing subjects with a short duration of statin therapy use with subjects with a long duration of statin therapy use, the mean cholesterol response measurement was similar for both the groups.
Regarding the genotype distributions of the CETP polymorphism, given in Table 3 , both in the discovery cohort and in the replication cohort a difference in genotype frequency between the source population and the study population was observed. In the study population, a lower frequency of subjects homozygous for the variant genotype was observed, and a higher frequency of subjects homozygous for the major allele, compared with the source population. An explanation for this difference might be that CETP genotype is related to the indication for statin therapy. In our population, the CETP genotype was related to HDL-cholesterol: subjects with a variant allele had a significantly higher baseline HDL-cholesterol, whereas the baseline total cholesterol concentration was equivalent to subjects homozygous for the major allele. Therefore, subjects with a variant allele have a better ratio between HDL and LDL cholesterol, and may be less likely candidates for statin therapy. This may explain the fact that in the study population of only statin users we observed fewer subjects homozygous for the variant genotype. However, this does not influence the validity of our findings, as our study population only consisted of statin users.
Potential limitations of our study should be considered. Selection bias is unlikely as missing of blood samples and difficulties with genotyping are not related to CETP and APOA1 genotype. Information bias is not likely, as genotype data, data on cholesterol measurements, and prescription data of statin therapy were collected prospectively without prior knowledge of the aim of the study. We controlled for potential confounding factors such as age, gender, baseline total cholesterol, baseline HDL-cholesterol and statin dose in the linear regression analysis, in which we investigated potential effect modification by genotype of the relationship between statin therapy and cholesterol response. Furthermore, because statins primarily have their effect on serum LDL-cholesterol concentration, we preferred to consider serum LDL cholesterol concentrations in response to statin therapy as our outcome variable of interest, instead of serum total cholesterol concentrations. Because LDLcholesterol was determined less frequently in the Rotterdam Study, we unfortunately could not take this measurement as the outcome variable, as we had not enough power because of small sample size. Equally, we had an insufficient number of subjects to take D cholesterol, the difference between serum cholesterol concentration before and after start of statin therapy, as our outcome variable of interest. If we could have taken the D cholesterol as our outcome variable, this would allow us to include SNPs that were related to both baseline total cholesterol concentration and serum total cholesterol concentration under statin therapy. For example, we had included a polymorphism in the APOE gene, which is one of the most replicated statin pharmacogenetic interactions. [36] [37] [38] [39] In this study, the polymorphism in the APOE gene had an effect on serum total cholesterol concentration under statin therapy, but was excluded because it was also related to baseline total cholesterol concentration. Finally, we could not exclude that we did not find a significant association for some of the remaining SNPs, due to a lack of power.
Our study has several strengths. An advantage of the Rotterdam Study is the prospective ascertainment of risk factors and outcome variables over a relatively long period of follow-up, through which extensive information is available for use in the analysis. Also, the Rotterdam Study has a population-based character, which reduces the risk of selection bias. Another strength of our study is the replication in an independent cohort to minimize the chance of reporting a false-positive association, however, the fact that our replication sample is collected from the same general population means that the replication does not add information on the generalizability to other populations.
In conclusion, we found that the CETP rs1532624 polymorphism was associated with total cholesterol concentration in response to statin therapy in a cohort of elderly European statin users and an independent replication sample in the general population. The findings in this study may explain a small part of the interindividual varia-bility in cholesterol response to statin therapy, although further research is recommended to define the genetic profile that predicts response to statin therapy.
